Fundraising FoxBellerophon Therapeutics
Warren, US · Founded 2015 · Delaware corporation · 1 known investors
Find your way into Bellerophon Therapeutics
Sign up to see every warm intro you have to Bellerophon Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Bellerophon Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
PS
Parag ShahVice President of Business Operations
MD
Martin DekkerVice President of Engineering and Manufacturing
PF
Peter FernandesChief Executive Officer / Principal Executive Officer2021–2023Peter Fernandes holds the position of Chief Regulatory and Safety Officer at Bellerophon Therapeutics, where he oversees regulatory strategy, pharmacovigilance, and quality management systems for the company's drug-device combination products in development for pulmonary conditions.
FT
Fabian TenenbaumChief Executive Officer and Director
DQ
Deborah QuinnChief Medical Officer
MM
Martin MeglassonExecutive
RH
Reinilde HeyrmanExecutive
DA
David AbramsExecutive
MN
Manesh NaiduExecutive
Board
AM
RN
Robert NelsenBoard director
AW
Adam WeinsteinBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$25M disclosed across 4 rounds · 2014–2017
▶$23.4MraisedOct 2017 · 11 investors · PharmaceuticalsRule 506(b)
▶$23.4MraisedOct 2017 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jens LuehringDirector
- Mary Ann CloydDirector
- Adam B. WeinsteinDirector
- Martin DekkerExecutive Officer
- Deborah A. QuinnExecutive Officer
- Amy EdmondsExecutive Officer
- Scott BruderDirector
- Jonathan M. PeacockDirector
- Peter FernandesExecutive Officer
- Parag ShahExecutive Officer
- Andre V. MouraDirector
- Daniel TasseDirector
- Naseem P. AminDirector
- Megan SchoepsExecutive Officer
- Fabian TenenbaumExecutive Officer, Director
- Offering amount
- $23.4M
- Amount sold
- $23.4M
- Sales commissions
- $650K
- Placement agents
- Angel Pond Capital LLC
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$1.6MraisedMay 2017 · 7 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedMay 2017 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Naseem AminDirector
- Jens LuehringDirector
- Mary Ann CloydDirector
- Parag ShahExecutive Officer
- Martin DekkerExecutive Officer
- Andre MouraDirector
- Peter FernandesExecutive Officer
- Jonathan PeacockDirector
- Scott BruderDirector
- Daniel TasseDirector
- Fabian TenenbaumExecutive Officer, Director
- Deborah QuinnExecutive Officer
- Adam WeinsteinDirector
- Megan SchoepsExecutive Officer
- Amy EdmondsExecutive Officer
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- Sales commissions
- $210K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1raisedJul 2014 · 6 investors · PharmaceuticalsRule 506(b)
▶$1raisedJul 2014 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David AbramsExecutive Officer
- Aldo BelloniDirector
- Martin MeglassonExecutive Officer
- Manesh NaiduExecutive Officer
- Jonathan PeacockExecutive Officer, Director
- Howard PienDirector
- Daniel TasseDirector
- Adam WeinsteinDirector
- Matthew HoltDirector
- Robert NelsenDirector
- Andre MouraDirector
- Reinilde HeyrmanExecutive Officer
- Offering amount
- $1
- Amount sold
- $1
- First sale
- Jun 2014
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
▶$1raisedFeb 2014 · 4 investors · PharmaceuticalsRule 506(b)
▶$1raisedFeb 2014 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andre MouraDirector
- Robert NelsenDirector
- Adam WeinsteinDirector
- Aldo BelloniDirector
- Daniel TasseExecutive Officer, Director
- Martin MeglassonExecutive Officer
- Howard PienDirector
- Reinilde HeyrmanExecutive Officer
- Bryan RobertsDirector
- David AbramsExecutive Officer
- Manesh NaiduExecutive Officer
- Matthew HoltDirector
- Offering amount
- $1
- Amount sold
- $1
- First sale
- Feb 2014
- Incorporated
- Limited Liability Company, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Bellerophon Therapeutics's investors?
- Bellerophon Therapeutics's investors include New Mountain Capital.
- How much funding has Bellerophon Therapeutics raised?
- Bellerophon Therapeutics has disclosed $25M raised across 4 rounds.
- Where is Bellerophon Therapeutics headquartered?
- Bellerophon Therapeutics is headquartered in Warren, US.